Abstract | BACKGROUND: METHODS: We applied a variety of experimental methods such as immunoblotting, MTT, si- RNA, and animal models, to demonstrate the relationship between EGFR and low-density lipoprotein receptor (LDLR) and the effects of statin monotherapy, and TKI monotherapy, and their combination on cell proliferation at the cell level and animal level. RESULTS: LDLR has a positive correlation with EGFR, EGFR signaling upregulates LDLR expression through the SREBP-1 dependent pathway, EGFR mutation cells count on lipids to survive and grow. Combined with a molecule-targeted drug, atorvastatin not only enhances the treatment effect in vitro, but also mitigates the growth of NSCLC in vivo. In this animal experiment, the combination medicine ( atorvastatin with TKI) has a better tumor suppression effect on NSCLC. In HCC827 cell line, the average tumor shrinkage is about 68% in Gefitinib group, and about 49% in atorvastatin group, but about 89% in combination group. In H1975 cell line, the average tumor shrinkage is about 18% in Osimertinib group, and about 8% in atorvastatin group, but about 44% in combination group. CONCLUSIONS: the combination of an EGFR-TKI and a statin for EGFR mutant NSCLC may be a novel tumor inhibiting treatment.
|
Authors | Youli Luo, Yunpeng Yang, Peijian Peng, Jianhua Zhan, Zhihui Wang, Zhiquan Zhu, Zhonghan Zhang, Lin Liu, Wenfeng Fang, Li Zhang |
Journal | Translational lung cancer research
(Transl Lung Cancer Res)
Vol. 10
Issue 1
Pg. 128-142
(Jan 2021)
ISSN: 2218-6751 [Print] China |
PMID | 33569299
(Publication Type: Journal Article)
|
Copyright | 2021 Translational Lung Cancer Research. All rights reserved. |